Archana Bangalore
Family Medicine · Clovis, CANPI 1801349683
Payments from drug & device makers
Across 112 payments — averaging $856.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$94K
- Lilly USA, LLC$327
- Novo Nordisk$256
- AbbVie$145
- Bayer$130
- Cranial Technologies, Inc$92
- plus $507 from 16 others
What the payments were for
- Consulting fees$94,00098%
- Food & beverage$1,4572%
- Education$4750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $94,475 |
| Lilly USA, LLC | 17 | $327 |
| Novo Nordisk | 13 | $256 |
| AbbVie | 6 | $145 |
| Bayer | 7 | $130 |
| Cranial Technologies, Inc | 6 | $92 |
| Pfizer | 4 | $81 |
| Shield Therapeutics Inc | 3 | $72 |
| Ultragenyx Pharmaceutical Inc. | 4 | $70 |
| Sanofi Pasteur Inc. | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Dynavax Technologies Corporation | 1 | $29 |
| GSK | 1 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Verrica Pharmaceuticals Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Seqirus USA Inc | 1 | $13 |
| Phadia US Inc. | 1 | $13 |
How this compares
$95,932 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $67,019 |
| JardianceEmpagliflozin | 45 | $31,688 |
| EliquisApixaban | 31 | $29,602 |
| RybelsusSemaglutide | 16 | $21,176 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $7,276 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $5,221 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $2,310 |
| Atorvastatin Calcium | 211 | $2,205 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,607 |
| Famotidine | 132 | $1,516 |
| Duloxetine Hcl | 48 | $1,152 |
| Hydroxyzine Hcl | 48 | $1,006 |
| Gabapentin | 79 | $989 |
| Ziprasidone Hcl | 12 | $918 |
| Levothyroxine Sodium | 144 | $862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $256 | $88,19578 claims |
| Boehringer IngelheimJardiance | $22 | $31,68845 claims |
| PfizerEliquis | $81 | $29,60231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Clovis
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.